Marketing & Sales

Alvotech and Cipla Gulf enter into a partnership for the commercialization of key biosimilar in select emerging markets

Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.

Sandoz launches oncology generic gefitinib in 13 EU countries

Sandoz has announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment.

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Swiss drugmaker Novartis has completed the acquisition of dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn (£2.6bn) upfront in cash.

Dr. Reddy’s to sell neurology branded products to Upsher-Smith Laboratories

Dr. Reddy’s Laboratories has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg (formerly referred to as “DFN-02”), which are commercialized through its wholly owned subsidiary, Promius Pharma.

Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years

Debiopharm and Ipsen announced renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets.

Theramex signs exclusive licensing and supply rights deal with TherapeuticsMD

UK-based Theramex has agreed to acquire exclusive licensing and supply rights from TherapeuticsMD to commercialise BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the US.

Neuraxpharm to launch its first probiotic product in Europe

Neuraxpharm Group, a provider of treatments for central nervous system (CNS) disorders, is set to introduce its first probiotic in the European market.

Chiesi to acquire licensing rights to Santhera’s LHON drug Raxone

Italy-based Chiesi Farmaceutici (Chiesi Group) has agreed to buy the licensing rights of Raxone (idebenone), an approved drug for Leber's hereditary optic neuropathy (LHON) in Europe, from Swiss pharma company Santhera Pharmaceuticals in a deal worth up to CHF105m (£82.5m).

Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn

Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.